MediciNova gains approval to present abstract on ALS therapy MN-166
Category: #Health  By Paroma Bhattacharya  Date: 2019-07-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

MediciNova gains approval to present abstract on ALS therapy MN-166

The company CMO, Kazuko Matsuda will present the abstract titled “Interaction (nonuniformity) of ALS Progression and the Efficacy of MN-166 (ibudilast)” at the 30th International Symposium.

MediciNova, Inc., a biopharmaceutical organization focused on developing small-molecule therapeutics for the treatment of diseases that lack clinical cure, recently announced that an abstract concerning its completed clinical trial of MN-166 (ibudilast) in ALS has been approved for presentation at the 30th International Symposium on Amyotrophic Lateral Sclerosis/Motor Neurone Disease (ALS/MND), scheduled in Perth, Australia. 

Speaking on the move, Dr. Yuichi Iwaki, President and Chief Executive Officer, MediciNova, said that the company is delighted to present its research on ALS at the 30th International Symposium on ALS/MND. He said that their firm will use this opportunity to share its study and results with all the ALS/MND researchers, patients and clinicians who initially laid the foundation of design and implementation of its upcoming ALS trial.  

Reportedly, the pilot was a double-blind, randomized, placebo-controlled study which involved six-month treatment period accompanied by a six-month open-label extension. In collaboration with Carolinas Neuromuscular/ALS-MDA Center’s Director, Dr. Benjamin Rix Brooks, MediciNova offered patients a dose of 60 mg of MN-166 per day in both early and last stage of ALS.

For the record, amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that damages nerve cells in the spinal cord and the brain. The nerves lose the ability to prompt specific muscles, which makes the muscles weak. The condition affects voluntary movement of patients which results to complete paralysis in the later stages. Generally, an ALS patient’s life expectancy lasts between 2-5 years.

However, MN-166 (ibudilast)'s neuroprotective and anti-neuroinflammatory actions provide the rationale for treatment of ALS, progressive MS (multiple sclerosis) and other neurological diseases like glioblastoma (GBM), and substance addiction/abuse. These actions have also been demonstrated in preclinical and clinical studies, cite reports.

Source Credit: https://investors.medicinova.com/news-releases/news-release-details/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-4



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
By Paroma Bhattacharya

Clinical trials play a vital role in developing new treatments that could immensely improve a person’s living. Today, researchers and pharmaceutical company are working hard for making breakthroughs in psoriasis ...

Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
By Paroma Bhattacharya

Immune thrombocytopenia (ITP) is a type of blood abnormality that creates a shortage of blood cell fragments known as platelets required for normal blood clotting. While children with ITP get cured without treatme...

Indian social commerce startup Mall91 raises $7.5M in Series A round
Indian social commerce startup Mall91 raises $7.5M in Series A round
By Paroma Bhattacharya

  • Mall91 reportedly plans on using the acquired funds for product development, boosting hiring and driving supply chain efforts, and realizing its global expansion ambitions.